USPTO Patent for Anti-CD123 Immunoconjugates Treating AML

The USPTO has published a patent application (US20260083749A1) for anti-CD123 immunoconjugates, such as pivekimab sunirine, for treating acute myeloid leukemia (AML). The patent covers methods of use as monotherapies or in combination with other agents to achieve remission or prepare patients for transplant.

USPTO Patent Application: Compositions for Mitochondrial Health

The USPTO has published a patent application (US20260083747A1) detailing compositions for supporting mitochondrial health using methylthioninium salts combined with other compounds. The application was filed on October 30, 2024, by inventors Darren Lopez and Dan Schmidt.

Reduced Dosing Regimens for Glaucoma Treatment Methods

The USPTO has published a patent application (US20260083746A1) detailing methods for treating open-angle glaucoma by transitioning patients to a once-daily dosing regimen. The proposed treatment involves a pharmaceutical composition containing timolol, brimonidine, dorzolamide, and bimatoprost.

USPTO Patent Application for Visual Pathway Strengthening Methods

The USPTO has published a new patent application (US20260083744A1) for methods of treating visual impairment by strengthening visual pathways. The application was filed on September 26, 2025, by inventors Ming-Fai Fong and Robert D. Lamprecht.

USPTO Patent Application: Nucleoside Derivative for Inflammation Treatment

The USPTO has published a patent application (US20260083743A1) detailing a nucleoside derivative for preventing and treating inflammation. The application, filed by WEST CHINA HOSPITAL OF SICHUAN UNIVERSITY, claims the derivative offers better efficacy and fewer side effects than existing treatments like indometacin.

Patent Application for Cancer Treatment with Azenosertib and HRD Biomarker

The USPTO has published a patent application (US20260083742A1) detailing methods for treating cancer by administering azenosertib to subjects selected based on homologous recombination repair deficiency (HRD). The application was filed on December 1, 2025.

Sotorasib Dosing Regimen Patent Application

The USPTO has received a patent application (US20260083741A1) for a sotorasib dosing regimen. The application, filed by Brett E. Houk and Panli Cardona, details methods for administering sotorasib to patients, particularly those with KRAS G12C-mutated cancer who also require treatment with a BCRP substrate like rosuvastatin.

USPTO Patent Application for Tavapadon in Parkinson's Disease Treatment

The USPTO has published a patent application (US20260083740A1) detailing methods for treating Parkinson's Disease using escalating doses of tavapadon. The application was filed on September 23, 2025, by inventor Sridhar Duvvuri.

USPTO Patent Application: Dietary Compositions for Health and Diabetes Treatment

The USPTO has published a patent application (US20260083739A1) for dietary compositions containing minerals and vitamins, intended for various health benefits including diabetes treatment, improved athletic performance, and immune support. The application was filed on December 2, 2025.

USPTO Patent Application: Modified Release Minoxidil for Hair Loss

The USPTO has published a patent application (US20260083738A1) detailing modified release minoxidil oral formulations for treating hair loss. The application, filed by Reid Waldman, describes compositions including minoxidil alone or with other active agents, and methods of treatment. This represents a new patent filing for a potential pharmaceutical product.